As of November 6, 2026, Kalaris Therapeutics, Inc. is a publicly traded company (Nasdaq: KLRS). Samsara BioCapital, L.P. reports holding 54.2%, a majority of its shares. No bankruptcy or receivership appears in its SEC Form 8-K filings. Passive holders reporting on Schedule 13G include RTW Investments (5.7%), Coastlands Capital LP (5.69%) (Schedule 13D/A, May 22, 2026).
Is this your company?
About to sign with, pay or invest in Kalaris Therapeutics, Inc.? See the free Snapshot first.
Free to see. No signup.
Is Kalaris Therapeutics, Inc. a real, registered company?
- Kalaris Therapeutics, Inc. files with the SEC under CIK 1754068 (its SEC filings).
- Its shares are listed under the ticker KLRS on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in Berkeley Heights, New Jersey, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under Kalaris Therapeutics, Inc. in our court records and SEC 8-K records (as of 2026-11-06).
- Leadership changes: the latest reported is Liisa Bayko, Chief Financial Officer (Form 8-K filed 2026-07-20). Check you are dealing with the people now in charge.
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Coastlands Capital LP (filed 2026-10-26).
Who are Kalaris Therapeutics, Inc.'s owners and officers?
Kalaris Therapeutics, Inc.: incorporated in Delaware; business address in Berkeley Heights, New Jersey; industry Biological Products, (No Diagnostic Substances) (Schedule 13G, 2026-10-26).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G, 2026-10-26 | Coastlands Capital LP | 5.69% |
| Schedule 13D/A, 2026-05-22 | Samsara Biocapital, L.P. | 54.2% |
| Schedule 13D/A, 2026-02-17 | Samsara Biocapital, L.P. | 56.5% |
| Schedule 13G, 2026-02-17 | Rtw Investments, LP | 5.7% |
| Schedule 13D/A, 2025-12-22 | Samsara Biocapital, L.P. | 56.5% |
| Schedule 13G/A, 2025-07-29 | Invus Public Equities, L.P. | 1.5% |
Questions about who owns Kalaris Therapeutics, Inc.
Who owns Kalaris Therapeutics, Inc.?
On this page, 3 holders' latest ownership filings report 5% or more of Kalaris Therapeutics, Inc.: Samsara Biocapital, L.P. (54.2%, Schedule 13D/A, filed 2026-05-22), Rtw Investments, LP (5.7%, Schedule 13G, filed 2026-02-17) and Coastlands Capital LP (5.69%, Schedule 13G, filed 2026-10-26).
Who are the largest shareholders of Kalaris Therapeutics, Inc.?
By the share each holder's latest filing reports, the largest holders of Kalaris Therapeutics, Inc. on this page are Samsara Biocapital, L.P. (54.2%), Rtw Investments, LP (5.7%) and Coastlands Capital LP (5.69%).
When did Samsara Biocapital, L.P. buy into Kalaris Therapeutics, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Samsara Biocapital, L.P. on this page is the Schedule 13D/A, filed 2025-12-22, reporting 56.5%; its latest, Schedule 13D/A filed 2026-05-22, reports 54.2%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 6 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Kalaris Therapeutics, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Kalaris Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Kalaris Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
11 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
| Filed | Person | Role | Change | Effective |
|---|---|---|---|---|
| Form 8-K, 2026-07-20 | Liisa Bayko | Chief Financial Officer | appointed | 2026-07-20 |
| Form 8-K, 2026-07-20 | Liisa Bayko | appointed | ||
| Form 8-K, 2026-07-20 | Amy Vandekop | Controller | appointed | 2026-07-27 |
| Form 8-K, 2026-07-06 | Laurie Keating | Director | appointed | 2026-08-01 |
| Form 8-K, 2026-07-06 | Laurie Keating | appointed | 2026-08-01 | |
| Form 8-K, 2026-04-10 | Matthew Gall | Chief Financial Officer | departed | 2026-04-14 |
Which insiders own Kalaris Therapeutics, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- Samsara Opportunity Fund, L.P., a 10% owner: 12,915,520 shares (54.3% of shares outstanding), held indirectly through By Samsara BioCapital Partners, L.P. and 2 others, on a joint filing (Form 4, 2026-05-22).
- , L.P., a 10% owner: 12,915,520 shares (54.3% of shares outstanding), held indirectly through By Samsara BioCapital Partners, L.P. and 2 others, on a joint filing (Form 4, 2026-05-22).
- , a director and 10% owner: 12,915,520 shares (54.3% of shares outstanding), held indirectly through By Samsara BioCapital Partners, L.P. and 2 others, on a joint filing (Form 4, 2026-05-22).
- Samsara BioCapital GP, LLC, a 10% owner: 12,915,520 shares (54.3% of shares outstanding), held indirectly through By Samsara BioCapital Partners, L.P. and 2 others, on a joint filing (Form 4, 2026-05-22).
- Samsara Opportunity Fund GP, LLC, a 10% owner: 12,915,520 shares (54.3% of shares outstanding), held indirectly through By Samsara BioCapital Partners, L.P. and 2 others, on a joint filing (Form 4, 2026-05-22).
Shares outstanding: 23,804,981 as of 2026-08-04, from the company's latest SEC cover page.
How much has Kalaris Therapeutics, Inc. raised?
No fundraising or offering filing from Kalaris Therapeutics, Inc. is on file with us.
Keep reading
More on Kalaris Therapeutics, Inc. and the records around it.
Kalaris Therapeutics, Inc. elsewhere on the record
- 5%+ stake filings Oct 2026
- Leadership changes Jul 2026
Companies that share a holder
- Samsara BioCapital, L.P. also filed stake reports on 14 other companies: PMV Pharmaceuticals, Inc. (Sep 2026), Eloxx Pharmaceuticals, Inc. (Aug 2026), RANI THERAPEUTICS HOLDINGS, INC. (May 2026)
- Coastlands Capital LP also filed stake reports on 16 other companies: Sutro Biopharma, Inc. (Nov 2026), Bolt Biotherapeutics, Inc. (Nov 2026), Frazier Life Sciences Acquisition Corp. II (Oct 2026)
- Invus Public Equities, L.P. also filed stake reports on 24 other companies: City Therapeutics, Inc. (Oct 2026), Yarrow Bioscience, Inc. (Sep 2026), Abivax S.A. (Aug 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/kalaris-therapeutics